The use of estrogen in the treatment of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 8, Issue 2, 2001, Pages 133-137

  Tsang, K L ^a   Jiang, H ^a   Ramsden, D B ^b   Ho, S L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Catechol O methyltransferase (COMT); Estrogen; Parkinson's disease; Selective estrogen receptor modulators (SERM)

Indexed keywords

CATECHOL METHYLTRANSFERASE; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CONFERENCE PAPER; DOPAMINERGIC SYSTEM; DRUG EFFECT; ESTRUS CYCLE; HORMONE SUBSTITUTION; HUMAN; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE;

ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENSTRUAL CYCLE; METHYLTRANSFERASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SEX CHARACTERISTICS; SUBSTANTIA NIGRA;

EID: 0034899543     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00027-X     Document Type: Conference Paper

References (42)

1. Estrogen and movement disorders
2. Effects of estrogen on the basal ganglia
3. 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain
4. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats
5. Antidopaminergic effect of estrogens at the striatal level
6. Acute stimulatory effect of estradiol on striatal dopamine synthesis
7. Gender differences in Parkinson's disease
8. Prevalence of Parkinson's disease in the Parsi community of Bombay
9. Rising mortality from Parkinson's disease in Japan
10. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China
11. Epidemiology of parkinsonism: Incidence, classification and mortality
12. Menstrual-related fluctuations in Parkinson's disease
13. Menstrual cycle related changes in Parkinson's disease
14. Estrogens and the pathophysiology of Parkinson's disease
15. Decreased phenylethanolamine-N-methyltransferase and catechol-O-methyltransferase activity in rabbit adrenal glands during pregnancy
16. Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy
17. Changes of rat striatal neuronal membrane morphology and steroid content during the estrous cycle
18. Homovanillic acid levels in rat striatum during the oestrous cycle
19. The effect of estradiol on catechol-O-methyltransferase activity in rat liver
20. Human liver catechol-O-methyltransferase pharmacogenetics
21. Erythrocyte catechol-O-methyltransferase activity in a Swedish population
22. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription
23. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites
24. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model
25. Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum
26. Short-term effects of high dose 17B-estradiol in postmenopausal PD patients: A cross over study
27. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice
28. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro
29. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death
30. Estrogen protects primary cortical neurons from glutamate toxicity
31. Mechanisms of antiapoptotic effects of estrogen in nigral dopaminergic neurons
32. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine
33. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice
34. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice
35. The effect of estrogen replacement on early Parkinson's disease
36. Postmenopausal estrogen replacement therapy and Parkinson's disease: A population based study in Olmstead Country
37. Effects of hormonal replacement therapy on cognitive and motor function in women with Parkinson's disease
38. Postmenopausal estrogen use and Parkinson's disease with and without dementia
39. Effects of female sex steroids on Parkinson's disease in postmenopausal women
40. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
41. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease
42. Selective oestrogen receptor modulators